Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

Aim: Long-term survivors (LTS) after glioma recurrence while on bevacizumab (Bev) therapy are rarely reported in the current literature. The purpose of this case series is to confirm the existence of and describe a large cohort of recurrent glioma LTS treated with Bev (Bev-LTS). Patients & metho...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Liang Yen Liu, Matthew S Ji, Nhung T Nguyen, Frances E Chow, Donna M Molaie, Sean T Pianka, Richard M Green, Linda M Liau, Benjamin M Ellingson, Phioanh L Nghiemphu, Timothy F Cloughesy, Albert Lai
Natura:	Articolo
Lingua:	English
Pubblicazione:	Taylor & Francis Group 2019-06-01
Serie:	CNS Oncology
Soggetti:	bevacizumab glioblastoma glioma long term progression recurrence
Accesso online:	https://www.futuremedicine.com/doi/10.2217/cns-2019-0007

Documenti analoghi

Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab
di: Alissa Thomas, et al.
Pubblicazione: (2018-01-01)

A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab
di: Josie Hayes, et al.
Pubblicazione: (2016-10-01)

A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
di: Patrick Roth, et al.
Pubblicazione: (2020-06-01)

Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study
di: Bai X, et al.
Pubblicazione: (2024-11-01)

Bevacizumab in recurrent WHO grades II–III glioma
di: Soufyan Annakib, et al.
Pubblicazione: (2023-07-01)

Durable Complete Remission of a Brainstem Glioma Treated with a Combination of Bevacizumab and Cetuximab
di: Joan Manel Gasent Blesa, et al.
Pubblicazione: (2012-12-01)

BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
di: D. R. Naskhletashvili, et al.
Pubblicazione: (2015-04-01)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
di: Mesti Tanja, et al.
Pubblicazione: (2015-03-01)

Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
di: Moire Cuncannon, et al.
Pubblicazione: (2019-05-01)

The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis of randomized controlled trials
di: SiYao Wei, et al.
Pubblicazione: (2024-07-01)

Mechanism and significance of diffusion restriction followed by calcification in high-grade glioma treated with bevacizumab
di: Tomohiro Hosoya, et al.
Pubblicazione: (2024-11-01)

Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells
di: Mesti Tanja, et al.
Pubblicazione: (2018-11-01)

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
di: N. García-Romero, et al.
Pubblicazione: (2020-06-01)

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
di: Masahiro Nishikawa, et al.
Pubblicazione: (2021-03-01)

Cost-effectiveness analysis of bevacizumab combined with lomustine in the treatment of progressive glioblastoma using a Markov model simulation analysis
di: Zhaoyan Chen, et al.
Pubblicazione: (2024-05-01)

Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life
di: Kathleen Van Dyk, et al.
Pubblicazione: (2022-06-01)

Opportunities and Challenges for Successful Use of Bevacizumab in Pediatrics
di: Amy eBarone, et al.
Pubblicazione: (2013-04-01)

Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET
di: Hiroyuki Tatekawa, et al.
Pubblicazione: (2021-03-01)

Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma
di: Rebecca Kassubek, et al.
Pubblicazione: (2023-05-01)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
di: Celina Bihan, et al.
Pubblicazione: (2012-09-01)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
di: Eudocia Q. Lee, et al.
Pubblicazione: (2019-10-01)

Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center
di: Margarida Simão-Rafael, et al.
Pubblicazione: (2023-12-01)

Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping
di: Pia Banerjee, et al.
Pubblicazione: (2015-01-01)

Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine
di: Ramon F. Barajas, et al.
Pubblicazione: (2016-10-01)

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
di: George Ansstas, et al.
Pubblicazione: (2016-01-01)

Differential expression of the circadian clock network correlates with tumour progression in gliomas
di: Marina Petkovic, et al.
Pubblicazione: (2023-07-01)

Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
di: Barbara Castelli, et al.
Pubblicazione: (2023-09-01)

The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
di: Giovanni Luca Gravina, et al.
Pubblicazione: (2017-01-01)

Survival prediction using apparent diffusion coefficient values in recurrent glioblastoma under bevacizumab treatment: an updated systematic review and meta-analysis
di: Dong Liu, et al.
Pubblicazione: (2024-07-01)

Corrigendum: Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
di: Barbara Castelli, et al.
Pubblicazione: (2024-02-01)

Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab
di: Samy Ammari, et al.
Pubblicazione: (2021-07-01)

Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review
di: Oguz Ozel, et al.
Pubblicazione: (2016-08-01)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
di: Emil Lou, et al.
Pubblicazione: (2013-04-01)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
di: Seung Won Choi, et al.
Pubblicazione: (2018-05-01)

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
di: Minjie Fu, et al.
Pubblicazione: (2023-06-01)

Circadian Alterations in a Murine Model of Hypothalamic Glioma
di: José M. Duhart, et al.
Pubblicazione: (2017-10-01)

Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines
di: Valerie J. Marallano, et al.
Pubblicazione: (2024-03-01)

Selected cytostatic drugs in the treatment of brain glioma – literature review
di: Jarosław Bała, et al.
Pubblicazione: (2021-11-01)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
di: Lei She, et al.
Pubblicazione: (2022-08-01)

A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy
di: Shanmu Jin, et al.
Pubblicazione: (2024-03-01)